drugset / Trial / NCT00206050

Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po

NCT00206050

Phase 4 Completed 40 enrolled AstraZeneca
RandomizedCrossoverOpen-label

Summary

This Phase IV study is intended to compare intragastric acid suppression of oral esomeprazole (NEXIUM ® Delayed-Release Capsules) with that of oral pantoprazole (PROTONIX ® Delayed Release Tablets ), in subjects who continue to require acid-suppressive therapy following a course of intravenous (iv) pantoprazole (PROTONIX ® I.V. for Injection).

Timeline

Start
2004-09
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg Oral
Subject Pantoprazole Other / unclassified 40 mg Oral

Indications

No indication recorded.